Impact of betaine on hepatic fibrosis and homocysteine in nonalcoholic steatohepatitis - A prospective, cohort study

Sandeep Mukherjee, Tamara Bernard, Kusum Kharbanda, Anthony J. Barak, Michael F. Sorrell, Dean J. Tuma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Nonalcoholic steatohepatitis (NASH) is an important cause of cirrhosis and over the past decade has accounted for an increasing proportion of liver transplants in the United States. Unfortunately there is no treatment for NASH except for risk factor modification. The aims of our study were to assess the impact of betaine on liver function tests, homocysteine levels and hepatic fibrosis in a prospective cohort of NASH patients Materials and Methodology: Between July 2003 and June 2006, consecutive patients with NASH were screened to determine treatment eligibility. Eligibility criteria included elevated aminotransferases and a liver biopsy within twelve months of study entry satisfying the Brunt criteria for NASH. Patients were treated with betaine anhydrous 10 grams twice a day for one year. Liver function tests, homocysteine levels and liver biopsy were performed prior to and at the end of treatment. Outcomes were calculated using intention to treat analysis. Results: 35 patients were eligible. 23 patients completed treatment, seven were intolerant and five dropped out and were lost to follow up. Improvement or normalization in aminotransferases occurred in 62.9% of patients (p 0.05). Resolution or improvement in steatosis occurred in 57.1% (p

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalOpen Translational Medicine Journal
Volume3
Issue number1
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Betaine
Homocysteine
Fibrosis
Cohort Studies
Prospective Studies
Liver
Liver Function Tests
Transaminases
Biopsy
Intention to Treat Analysis
Lost to Follow-Up
Therapeutics
Non-alcoholic Fatty Liver Disease
Transplants

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Impact of betaine on hepatic fibrosis and homocysteine in nonalcoholic steatohepatitis - A prospective, cohort study. / Mukherjee, Sandeep; Bernard, Tamara; Kharbanda, Kusum; Barak, Anthony J.; Sorrell, Michael F.; Tuma, Dean J.

In: Open Translational Medicine Journal, Vol. 3, No. 1, 2011, p. 1-4.

Research output: Contribution to journalArticle

Mukherjee, Sandeep ; Bernard, Tamara ; Kharbanda, Kusum ; Barak, Anthony J. ; Sorrell, Michael F. ; Tuma, Dean J. / Impact of betaine on hepatic fibrosis and homocysteine in nonalcoholic steatohepatitis - A prospective, cohort study. In: Open Translational Medicine Journal. 2011 ; Vol. 3, No. 1. pp. 1-4.
@article{4dee9c6d67a6447782087448ca057958,
title = "Impact of betaine on hepatic fibrosis and homocysteine in nonalcoholic steatohepatitis - A prospective, cohort study",
abstract = "Introduction: Nonalcoholic steatohepatitis (NASH) is an important cause of cirrhosis and over the past decade has accounted for an increasing proportion of liver transplants in the United States. Unfortunately there is no treatment for NASH except for risk factor modification. The aims of our study were to assess the impact of betaine on liver function tests, homocysteine levels and hepatic fibrosis in a prospective cohort of NASH patients Materials and Methodology: Between July 2003 and June 2006, consecutive patients with NASH were screened to determine treatment eligibility. Eligibility criteria included elevated aminotransferases and a liver biopsy within twelve months of study entry satisfying the Brunt criteria for NASH. Patients were treated with betaine anhydrous 10 grams twice a day for one year. Liver function tests, homocysteine levels and liver biopsy were performed prior to and at the end of treatment. Outcomes were calculated using intention to treat analysis. Results: 35 patients were eligible. 23 patients completed treatment, seven were intolerant and five dropped out and were lost to follow up. Improvement or normalization in aminotransferases occurred in 62.9{\%} of patients (p 0.05). Resolution or improvement in steatosis occurred in 57.1{\%} (p",
author = "Sandeep Mukherjee and Tamara Bernard and Kusum Kharbanda and Barak, {Anthony J.} and Sorrell, {Michael F.} and Tuma, {Dean J.}",
year = "2011",
doi = "10.2174/1876399501103010001",
language = "English",
volume = "3",
pages = "1--4",
journal = "Open Translational Medicine Journal",
issn = "1876-3995",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Impact of betaine on hepatic fibrosis and homocysteine in nonalcoholic steatohepatitis - A prospective, cohort study

AU - Mukherjee, Sandeep

AU - Bernard, Tamara

AU - Kharbanda, Kusum

AU - Barak, Anthony J.

AU - Sorrell, Michael F.

AU - Tuma, Dean J.

PY - 2011

Y1 - 2011

N2 - Introduction: Nonalcoholic steatohepatitis (NASH) is an important cause of cirrhosis and over the past decade has accounted for an increasing proportion of liver transplants in the United States. Unfortunately there is no treatment for NASH except for risk factor modification. The aims of our study were to assess the impact of betaine on liver function tests, homocysteine levels and hepatic fibrosis in a prospective cohort of NASH patients Materials and Methodology: Between July 2003 and June 2006, consecutive patients with NASH were screened to determine treatment eligibility. Eligibility criteria included elevated aminotransferases and a liver biopsy within twelve months of study entry satisfying the Brunt criteria for NASH. Patients were treated with betaine anhydrous 10 grams twice a day for one year. Liver function tests, homocysteine levels and liver biopsy were performed prior to and at the end of treatment. Outcomes were calculated using intention to treat analysis. Results: 35 patients were eligible. 23 patients completed treatment, seven were intolerant and five dropped out and were lost to follow up. Improvement or normalization in aminotransferases occurred in 62.9% of patients (p 0.05). Resolution or improvement in steatosis occurred in 57.1% (p

AB - Introduction: Nonalcoholic steatohepatitis (NASH) is an important cause of cirrhosis and over the past decade has accounted for an increasing proportion of liver transplants in the United States. Unfortunately there is no treatment for NASH except for risk factor modification. The aims of our study were to assess the impact of betaine on liver function tests, homocysteine levels and hepatic fibrosis in a prospective cohort of NASH patients Materials and Methodology: Between July 2003 and June 2006, consecutive patients with NASH were screened to determine treatment eligibility. Eligibility criteria included elevated aminotransferases and a liver biopsy within twelve months of study entry satisfying the Brunt criteria for NASH. Patients were treated with betaine anhydrous 10 grams twice a day for one year. Liver function tests, homocysteine levels and liver biopsy were performed prior to and at the end of treatment. Outcomes were calculated using intention to treat analysis. Results: 35 patients were eligible. 23 patients completed treatment, seven were intolerant and five dropped out and were lost to follow up. Improvement or normalization in aminotransferases occurred in 62.9% of patients (p 0.05). Resolution or improvement in steatosis occurred in 57.1% (p

UR - http://www.scopus.com/inward/record.url?scp=80053493966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053493966&partnerID=8YFLogxK

U2 - 10.2174/1876399501103010001

DO - 10.2174/1876399501103010001

M3 - Article

AN - SCOPUS:80053493966

VL - 3

SP - 1

EP - 4

JO - Open Translational Medicine Journal

JF - Open Translational Medicine Journal

SN - 1876-3995

IS - 1

ER -